Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of efruxifermin versus placebo in compensated cirrhosis due to NASH/MASH
MOH_2024-09-22_013657Phase 3Recruiting
- Sponsor
- Akero Therapeutics
- Start
- Sep 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Efruxifermin with Placebo (2 arms). Primary endpoints: All-cause mortality and liver-related clinical outcomes measured by event-free survival and Fibrosis regression without worsening of NASH/MASH. Started Sep 2024; status: recruiting.
02
Drugs
efruxifermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on MOH_2024-09-22_013657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-22_013657.